HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Somatostatin in diabetic retinopathy.

Abstract
Diabetic retinopathy is a leading cause of legal blindness in the adult population (30-70 year olds). The anatomical changes that occur in the retina during the course of disease are well defined in the literature but the causes are not yet fully understood. Laser photocoagulation of the retina and vitrectomy are currently used to treat diabetic retinopathy but the procedures are invasive and provide only temporary protection. The use of long-acting analogues of the naturally occurring peptide, somatostatin, has been considered by some a promising therapeutic option for retinopathy over the last decade. Experimental evidence supports its use in diabetic retinopathy but further clinical evidence, from larger treatment groups of longer trial duration, is required. Improved analogues with increased selectivity and modified bi-specific analogues are currently emerging and may help to make the use of somatostatin analogues a more realistic option in the treatment of diabetic retinopathy.
AuthorsR Croxen, G S Baarsma, R W A M Kuijpers, P M van Hagen
JournalPediatric endocrinology reviews : PER (Pediatr Endocrinol Rev) Vol. 1 Suppl 3 Pg. 518-24 (Aug 2004) ISSN: 1565-4753 [Print] Israel
PMID16444186 (Publication Type: Journal Article, Review)
Chemical References
  • Somatostatin
  • Octreotide
Topics
  • Animals
  • Diabetic Retinopathy (drug therapy)
  • Humans
  • Octreotide (therapeutic use)
  • Somatostatin (analogs & derivatives)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: